• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2006 Fiscal Year Final Research Report Summary

Identification of minor histocompatibility antigens as targets for allogeneic adoptive immunotherapy against hematological malignancies.

Research Project

Project/Area Number 17591025
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionAichi Cancer Center Research Institute

Principal Investigator

AKATSUKA Yoshiki  Aichi Cancer Center Research Institute, Division of Immunology, Section Head, 腫瘍免疫学部, 室長 (70333391)

Project Period (FY) 2005 – 2006
Keywordsminor histocompatibility antigen / cytotoxic T lymphocyte / adoptive immunotherapy / hematological malignancies)
Research Abstract

Cytotoxic T lymphocytes (CTL) specific for minor histocompatibility antigens (mHAgs) whose tissue expression is limited to hematopoietic cells are useful for immunotherapy of relapsed leukemia/lymphoma following allogeneic hematopoietic cell transplantation (HCT). We have identified 4 mHAgs including 3 novel mHAgs and an HA-1 mHAg presented by HLA-A2 subtype other than the original HLA-A^*0201.
(1)We found HLA-A^*3101 and-A^*3303-restricted mHAg epitopes whose expression was controlled by an SNP in Cathepsin H (CTSH) gene. CTSH protein was expressed relatively ubiquitously, but its expression was highest in monomyelocytic cells. Nevertheless, CTL clones specific for CTSH did not lyse any non-hematopoietic cells, although the reason remained unclear.
(2)A mHAg gene recognized by HLA-B44-restricted CTL was localized to 18q23 by linkage analysis. Expression cloning revealed that the mHAg was encoded by a splice variant of HMSD gene. The variant was produced by alternative splicing due to an SNP in the intron 2 SD site leading to exclusion of exon 2, which is a novel mechanism in mHAg generation. The HMSD was found to be highly expressed in myeloid and plasma cell malignancies, suggesting the HMSD encoded mHAg(s) should serve as a good target for immunotherapy against AML and myeloma.
(3)By using a 29-mer peptide spanning HA-1^H epitope in the middle, we isolated HLA-A^*0206-restricted CTL from posttransplant peripheral blood samples of a patient receiving HA-1 mismatched transplant. The epitope was found to be identical to that presented by HLA-A^*0201 molecule, indicating HA-1^H mHAg can also be presentable by HLA-A^*0206, which was totally unexpected from the known binding motif of HLA-A^*0206 molecule.
(4)We have started recruiting patients eligible for mHAg-based immunotherapy. The target mHAgs used in this clinical study so far are ACC-1, ACC-2 and HA-1, which are expected to cover more than 30% of Japanese patients receiving allogeneic transplantation.

  • Research Products

    (10 results)

All 2007 2006 2005

All Journal Article (9 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.2007

    • Author(s)
      Torikai H, et al.
    • Journal Title

      Bone Marrow Transplant. (In press)

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6 : the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitone.2007

    • Author(s)
      Morishima S, et al.
    • Journal Title

      Int. J. Cancer 120 (3)

      Pages: 594-604

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A^*0206.2007

    • Author(s)
      Torikai H, et al.
    • Journal Title

      Bone Marrow Transplant. (In press)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6 : the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.2007

    • Author(s)
      Morishima S, et al.
    • Journal Title

      Int. J. Cancer. 120 (3)

      Pages: 594-604

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] Characterization of murine CD160+ CD8+ T lymphocytes.2006

    • Author(s)
      Tsujimura K, et al.
    • Journal Title

      Immunol Lett. 106 (1)

      Pages: 48-56

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Bone marrow may be a reservoir of long-lived memory T cells specific for minor histocompatibility antigen.2006

    • Author(s)
      Akatsuka Y, et al.
    • Journal Title

      Br. J. Haematol. 135 (3)

      Pages: 413-414

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303.2006

    • Author(s)
      Torikai H, et al.
    • Journal Title

      Br. J. Haematol. 134 (4)

      Pages: 406-416

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A^*3101 and-A^*3303.2006

    • Author(s)
      Torikai H, et al.
    • Journal Title

      Br. J. Haematol. 134 (4)

      Pages: 406-416

    • Description
      「研究成果報告書概要(欧文)」より
  • [Journal Article] A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation.2005

    • Author(s)
      Terakura S, et al.
    • Journal Title

      Br. J. Haematol. 129

      Pages: 221-228

    • Description
      「研究成果報告書概要(和文)」より
  • [Patent(Industrial Property Rights)] LOC284293バリアント遺伝子並びに該遺伝子がコードするCD8+細胞傷害性Tリンパ球mHAエピトープペプチド及びその用途2007

    • Inventor(s)
      赤塚美樹, 他3名
    • Industrial Property Rights Holder
      愛知県
    • Industrial Property Number
      特願2006-152098
    • Filing Date
      2007-05-31
    • Description
      「研究成果報告書概要(和文)」より

URL: 

Published: 2008-05-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi